Healio

Pegcetacoplan yields kidney benefits in rare complement-mediated glomerular diseases

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
STAT

Is evolving research in complement inhibition a key to finding new medicines for rare diseases?

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Immune system plays a major role in brain damage after repeated concussions, study suggests

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
The American Journal of Managed Care

Novel Complement Therapies for Cold Agglutinin Disease

During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies. Neil Minkoff, MD: Let me ...
Healio

VIDEO: Positioning complement inhibitors for treatment of glomerular diseases

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The complement inhibitors are the latest ...
Business Wire

Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases

REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...
Seeking Alpha

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...
Business Wire

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

“Our CAN106 program for complement-mediated diseases is gaining momentum this year with the first public presentation of the Phase 1 clinical trial results at two major scientific conferences and the ...
Nasdaq

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – “Huntington’s Disease is a devastating, progressive movement disorder with no cure and no approved therapeutic options available to ...
Nature

Complement in ANCA-associated vasculitis: mechanisms and implications for management

Activation of the complement system through the alternative pathway is necessary for the development of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in animal models C5a has ...
The American Journal of Managed Care

Coverage for Complement Therapies for Cold Agglutinin Disease

Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease. Neil Minkoff, MD: I want to bring our payers back in ...